Implementation of the MOX Activity Monitor in Hospitalized Geriatric Rehabilitation
Launched by KU LEUVEN · Aug 8, 2025
Trial Information
Current as of August 24, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This study is looking at how much older adults recovering from hip fractures, strokes, or frailty move around while they are in the hospital for rehabilitation. The researchers will use a small device called the MOX activity monitor, which can track when patients are walking, standing, or resting. By understanding patients’ daily activity, the study hopes to find better ways to support their recovery and create personalized rehab plans that help them get stronger.
To take part, patients need to be 70 years or older and currently staying in the geriatric rehabilitation ward at UZ Leuven, campus Pellenberg. They must be able to understand instructions and perform simple physical tests like walking 10 meters and gripping with their hand. Participants will wear the MOX monitor while doctors compare its data with usual performance tests. This study is not yet recruiting, but it aims to improve how doctors track recovery and care for older patients in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Hospitalized on the geriatric rehabilitation ward of UZ Leuven, campus Pellenberg
- • 70 years or older
- • Signed informed consent
- Exclusion Criteria:
- • Cognitive impairment making it impossible to understand instructions
- • Unable to perform the standard of care physical tests 10mWT, BBS, and handgrip
About Ku Leuven
KU Leuven, a prestigious research university located in Belgium, is renowned for its commitment to advancing medical science and improving patient care through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, KU Leuven integrates cutting-edge research with clinical practice, facilitating the development of new therapeutic strategies and medical technologies. The institution's robust infrastructure and expertise in various fields, including biotechnology, pharmacology, and public health, position it as a leader in conducting high-quality clinical research that adheres to rigorous ethical standards and regulatory requirements. Through its clinical trials, KU Leuven aims to contribute significantly to the global biomedical landscape and enhance health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pellenberg, , Belgium
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported